Physician profile
Ildiko Babka
NPI 1881705507
$1,077.25
in general payments reported to CMS, 2019-2025
19 companies · $129 in 2025
The $129 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $105 · 2021: $164 · 2022: $188 · 2023: $150 · 2024: $105 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $173.24 | 2019-2022 | |
| Novo Nordisk INC | $164.11 | 2020-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $108.88 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Pfizer INC. | $95.76 | 2019-2025 | |
| Lilly USA, LLC | $79.32 | 2019-2023 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $71.63 | 2020-2021 | |
| Sanofi Pasteur INC. | $69.27 | 2019-2023 | |
| Abbott Laboratories | $59.20 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $55.26 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $51.66 | 2020-2025 | |
| Kerr Corporation | $22.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.88 | 2024 | Ofev |
| Amgen INC. | $18.41 | 2025 | Otezla, Repatha |
| Abbvie INC. | $17.79 | 2025 | |
| Athena Bioscience, LLC | $17.31 | 2024 | Qdolo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.55 | 2019 | |
| Vapotherm INC | $13.25 | 2023 | Vapotherm |
| Supernus Pharmaceuticals, INC. | $13.22 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ildiko Babka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.